Search
Pimagedine
go.drugbank.com/drugs/DB05383InvestigationalIt is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. … It is beneficial in treating patients with diabetic nephropathy.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnCurrently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.
Categories: Venombin ACatridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … When supplied as the recombinant form, Coagulation Factor XIII A-Subunit (Recombinant) binds to free human FXIII B-subunit resulting in a heterotetramer (rA2B2) with a similar activity profile and half-life
Synonyms: Factor XIII A-Subunit (Recombinant), Coagulation Factor XIII A-Subunit (recombinant)Pamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]
Products: MENEDRON-L 15 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (4 FLAKON), MENEDRON-L 30 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (3 FLAKON)Elacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.
Gallamine triethiodide
go.drugbank.com/drugs/DB00483ApprovedWithdrawnA synthetic nondepolarizing blocking drug. … It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
Omapatrilat
go.drugbank.com/drugs/DB00886ExperimentalOmapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). … The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling.
Categories: Agents Acting on the Renin-Angiotensin SystemDroloxifene
go.drugbank.com/drugs/DB15641ExperimentalIt may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM).
Categories: Compounds used in a research, industrial, or household settingFormic acid
go.drugbank.com/drugs/DB01942ApprovedInvestigationalIt is commonly used as a preservative and antibacterial agent in livestock feed. … It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings.
Selenomethionine
go.drugbank.com/drugs/DB11142ApprovedInvestigationalSelenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans. … *In vivo*, selenomethionine plays an essential role in acting as an antioxidant, where it depletes reactive oxygen species (ROS) and aids in the formation and recycling of glutathione, another important